PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Protestogen Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2019
Price : $35 *
At a glance
- Drugs Ethinylestradiol/levonorgestrel (Primary) ; Levonorgestrel (Primary) ; Medroxyprogesterone (Primary)
- Indications Endometriosis; Pelvic pain
- Focus Therapeutic Use
- Acronyms PRE-EMPT
- 28 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Jan 2019 Recruitment completion is expected on 28 Feb 2019 according to ISRCTN: Current Controlled Trials record.
- 28 Jan 2019 Status changed from active, no longer recruiting to recruiting.